Shares in pharmaceutical giant GSK have been downgraded by UBS. The bank has downgraded GSK shares to neutral from a previous buy rating.
Despite strong performance since 2011, UBS has taken to downgrade the stock for a number of reasons.
Analysts at the bank believe GSK has less score for performance versus peers and has reduced its sales forecast for the company by 2% in 2013.
Its target price has been reduced to 1525p by the bank.